DIRS.INFO The most relevant business & tech news

☆ Cramer's Lightning Round: Robinhood is a buy
▼ + stars: | 2024-10-10 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Micron's year-to-date stock performance. Stock Chart Icon Stock chart icon American Tower's year-to-date stock performance. Stock Chart Icon Stock chart icon ADMA Biologics' year-to-date stock performance. Stock Chart Icon Stock chart icon Robinhood's year-to-date stock performance. Stock Chart Icon Stock chart icon CVS's year-to-date stock performance.

Persons: Howmet, Modine, ADMA Biologics, ADMA Organizations: Dominion Freight, Old Dominion Freight, Union Pacific, Micron, Howmet Aerospace, Modine

☆ Lightning Round: Buy Robinhood, says Jim Cramer
▼ + stars: | 2024-10-10 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Buy Robinhood, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Old Dominion, Micron, American Tower, Howmet Aerospace, Modine Manufacturing, ADMA Biologics, Robinhood, and CVS.

Persons: Jim Cramer, ADMA Organizations: Dominion, Micron, Howmet Aerospace, Modine, CVS

☆ Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
▼ + stars: | 2024-10-02 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of its pipeline. Lilly says the facility will be the first of its kind to combine research and production in a single location. It will be near a $9 billion manufacturing complex Lilly is building in Lebanon, Indiana, to produce pharmaceutical ingredients like tirzepatide, the active ingredient in Mounjaro and Zepbound.

Persons: Eli Lilly, Mounjaro, Lilly, David Ricks, –, Dan Skovronsky Organizations: Lilly, Foundry, Indianapolis, Novo Nordisk's Ozempic Locations: Indianapolis, Lebanon , Indiana, tirzepatide

☆ A promising cancer treatment is poised for explosive growth, says Redburn Atlantic. These stocks are on its buy list
▼ + stars: | 2024-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. To treat cancer, targeted radiopharmaceutical therapy directly goes after tumors with radiation by binding a radioactive particle to a targeting molecule. Delving into diagnostics There are also opportunities in the radiopharma diagnostics space, according to Redburn Atlantic. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.

Persons: Ed Ridley, Eli Lilly, Myers, Ridley, Astra's, Lantheus Organizations: Big pharma, Novartis, Mariana Oncology, Biopharma, Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, GE Healthcare Technologies, Lantheus Holdings, GE Healthcare, GE Locations: Bristol, radiopharmaceuticals

☆ Dr. Reddy's Laboratories: India 'will be our number one market'
▼ + stars: | 2024-07-30 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Reddy's Laboratories: India 'will be our number one market'Erez Israeli of Dr. Reddy's Laboratories says the company is "absolutely planning to play" in the biologics space, and while the U.S. remains a key market for the company, India and other markets will grow faster.

Organizations: Reddy's Laboratories Locations: India, U.S

☆ We're raising our price target on Danaher stock as it sheds a major overhang
▼ + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

That improvement in the bioprocessing end market is super important because it has been a huge overhang for Danaher shares, and the life sciences space in general. We were concerned about the bioprocessing market after rival Sartorius cut its guidance last week. The management team has effectively navigated the bioprocessing slowdown better than others and kept expectations managed — a big reason we've stuck by the stock during a difficult few quarters. Based on these strong results and the improving bioprocessing market, we are raising our price target to $295 from $280 and reiterating our 1 rating. All three operating segments are expected to post sales decline rates in the low single digits.

Persons: Sartorius, Rainer Blair, Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: Club, Revenue, LSEG, Management, Diagnostics, Leica, Beckman Coulter Diagnostics, Cepheid, CNBC, Getty Locations: bioprocessing, Danaher, U.S, Europe, China, Bioprocessing

☆ Cramer's Lighting Round: Pinterest is a buy
▼ + stars: | 2024-07-22 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Salesforce's year-to-date stock performance. Stock Chart Icon Stock chart icon ADMA Biologics' year-to-date stock performance. Stock Chart Icon Stock chart icon Ouster's year-to-date stock performance. Stock Chart Icon Stock chart icon Vertiv's year-to-date stock performance. Stock Chart Icon Stock chart icon Pinterest's year-to-date stock performance.

Persons: It's, ADMA Biologics, ADMA, it's, Suncor, Jim Cramer's Organizations: Suncor

☆ A summer wave of Covid-19 has arrived in the US
▼ + stars: | 2024-06-28 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +6 min

CNN —Covid-19 levels have been rising in the United States for weeks as new variants drive what’s become an annual summer surge. That’s enough time to offer protection during the winter respiratory virus season but probably after this summer’s wave has ebbed. On Thursday, the CDC recommended that everyone ages 6 months and older receive an updated Covid-19 vaccine for the 2024-25 season. Unlike flu and RSV, Covid-19 is constantly circulating; it doesn’t offer a reprieve. The changes are meant to “simplify RSV vaccine decision-making for clinicians and the public,” the agency said.

Persons: CNN —, ”, Robert Hopkins, ” Hopkins, Marlene Wolfe, “, Dr, Jerry Weir, Marcus Plescia, Plescia, Sanjay Gupta, ” CNN’s Jen Christensen Organizations: CNN, US Centers for Disease Control, CDC, National Foundation for Infectious Diseases, Stanford University, Emory University, Emory, WastewaterSCAN, FDA, Viral Products, Vaccines Research, FDA’s, Biologics, Association of State, Territorial Health, CNN Health Locations: United States, —, Covid

☆ Here are 9 stocks that can benefit from Fed interest rate cuts
▼ + stars: | 2024-06-13 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Housing We see Stanley Black & Decker as a major beneficiary of Fed rate cuts due to its link to the housing market. On the one hand, lower rates mean a bank like Wells Fargo makes less money on the money it lends. Biotech Danaher should also see some benefit as lower rates lead to improved funding dynamics for biotech companies. Like in housing, monthly payments become far more manageable at lower rates, and therefore affordability and demand, stand to increase. Salesforce , which has also highlighted more measured deal activity, might not benefit as much from lower rates.

Persons: Jerome Powell, Stanley Black, Decker, Stanley, That's, Wells, Morgan Stanley, SVB, Ford, We're, Jim Cramer's, Jim Cramer, Jim, David Paul Morris Organizations: Nasdaq, CNBC, Fed, Biotech, Silicon Valley Bank, Ford, Palo, Networks, Microsoft, Jim Cramer's Charitable, Bloomberg, Getty Locations: Wells, Wells Fargo, Silicon Valley, Colma , California

☆ Here are Friday's biggest analyst calls of the day: Nvidia, Tesla, Apple, 3M, Bumble, Nike, Walmart, Palantir & more
▼ + stars: | 2024-05-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Wedbush reiterates Apple as outperform Wedbush said it's standing by its outperform rating on shares of Apple . Bank of America reiterates Palantir as buy Bank of America said it's standing by its buy rating on shares of Palantir. Bank of America initiates Apogee Therapeutics at buy Bank of America said the biotech company has best-in-class potential. Bank of America upgrades Bumble to buy from neutral Bank of America sees "multiple expansion" for the dating app company. Bank of America reiterates Walmart as buy Bank of America said it's bullish heading into Walmart earnings on May 16.

Persons: Bernstein, Wedbush, Palantir, Wells, CRNC, Stifel, TD Cowen, Morgan Stanley, Raymond James, it's, Bumble, Lear, Tesla, Oppenheimer, Guggenheim Organizations: Nvidia, Citi, Cheesecake, Apple, Worldwide, " Bank of America, Bank of America, Mizuho, Apogee Therapeutics, Warner Brothers Discovery, HSBC, TPG, of America, Dominion, underperform Bank of America, Dominion Energy, Barclays, Nike, Walmart, Supercenters, Moffett Locations: WWDC, Palantir, OW, U.S

☆ Goldman Sachs just refreshed its conviction lists of global stocks — giving one 67% upside
▼ + stars: | 2024-05-06 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

Goldman Sachs just refreshed its lists of top global stock picks, adding some and removing others. The investment bank's "Conviction List - Directors' Cut" aims to offer investors a "curated and active" list of 15 to 25 buy-rated stocks. The stocks are selected by a subcommittee designated by the bank's Investment Review Committee for each region. Here are three of the latest additions to Goldman's directors' cut lists — for Asia-Pacific and Europe — that were given more than 30% upside potential in the next 12 months. Goldman has a target price of 11,850 British pence ($148.71) on the stock, giving it around 30.7% upside potential.

Persons: Goldman Sachs, Goldman, London Stock Exchange Goldman, Oliver Carruthers, Samsung Biologics Goldman, Ziyi Chen, Michele Della Vigna, — CNBC's Michael Bloom Organizations: bank's Investment, London Stock Exchange, Microsoft, Samsung, Korean, EU's Renewable Energy, . Locations: Asia, Pacific, Europe, Korean

☆ Generative AI will be designing new drugs all on its own in the near future
▼ + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com time to read: +12 min

An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.

Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ Opinion | Three Mothers’ Plea to the F.D.A.: Save Our Children
▼ + stars: | 2024-02-28 | by ( ) www.nytimes.com time to read: +1 min

To the Editor:Re “Why Can’t More Children Get the Treatment That Saved My Son’s Life?,” by Elizabeth Currid-Halkett (Opinion guest essay, Feb. 24):Our three children, ages 5 and 7, battle a rare, relentless and ultimately fatal disease called cystinosis. We recently found hope in the initial phase of a gene therapy clinical trial that was shown to be safe and yielded very promising results — a therapy that could one day save our children’s lives. Our biggest fear is that it will not be accessible to them or others in desperate need. We applaud Dr. Marks’s wisdom and perspective. reviewers’ initial rejection is a cautionary tale of how patient access to lifesaving therapies could be impeded by a narrow interpretation of efficacy.

Persons: Elizabeth Currid, Currid, Peter Marks, “ Organizations: Biologics

☆ This sector offers defensive and growth properties – along with some portfolio income
▼ + stars: | 2024-02-26 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +6 min

The health-care sector of the S & P 500 is up about 8% year to date, marking a sharp comeback from a largely flat 2023. Even as health care is making a comeback this year, investors shouldn't forget its defensive attributes. Back in 2022, when the S & P 500 fell 19.4%, the health-care sector slipped only 3.5% "When markets are challenged, health care can be a good place to be," Lyons added. Some of them speak to the growth aspects of health care and why you can play offense." Merger activity is another driver of growth in health care, as large pharmaceutical companies snap up nimble biotech firms that are at the forefront of developing treatments.

Persons: Dan Lyons, Janus Henderson, shouldn't, Lyons, ImmunoGen, Seamus Fernandez, Sotatercept, Cigna, Cantor Fitzgerald, Sarah James, Fred Imbert Organizations: Big Tech, . Healthcare, Janus, Janus Henderson Investors, U.S . Food, Drug Administration's Center, Drug, Research, FDA, Esai, Pharmaceuticals, CNBC Pro, Merck, Abbott Laboratories, AbbVie, CVS Health Locations: U.S

☆ New data shows asthma medicine may help reduce severe reactions in people with multiple food allergies
▼ + stars: | 2024-02-25 | by ( Amanda Musa | ) edition.cnn.com time to read: +9 min

CNN —A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. There is no cure for food allergies, and the only other FDA-approved treatment is Palforzia, an oral immunotherapy for peanut allergies in children between 4 and 17 years old. “But the reality is that most of our patients don’t just have peanut allergy,” Wood added. For people who have multiple severe food allergies and even moderate to severe allergic asthma, Casale says, Xolair might be the best treatment option. Xolair does not eliminate food allergies, and unlike with some environmental allergies such as pollen, many people never outgrow them, Casale added.

Persons: ”, Sharon Chinthrajah, “, ” Xolair, Robert Wood, ” Wood, Xolair, Wood, omalizumab, Thomas Casale, Palforzia, Casale, they’ve, ” Lindsey Mathias, Dr, Sanjay Gupta, Chinthrajah, “ We’re Organizations: CNN, New England, of Medicine, US Food and Drug Administration, Stanford University, of Allergy, Immunology, Johns Hopkins Children’s, Genentech, Novartis, FDA, National Institutes of Health, University of South, American Academy of Allergy Asthma, CNN Health, Xolair Locations: anaphylaxis, Eudowood, Johns, University of South Florida Tampa

☆ We are focused on consolidating our acquired businesses for the coming fiscal year: Biocon Biologics
▼ + stars: | 2024-02-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe are focused on consolidating our acquired businesses for the coming fiscal year: Biocon BiologicsShreehas Tambe of Biocon Biologics discusses the company's earnings results for the third quarter of fiscal year 2024 following its acquisition of pharmaceutical company Viatris.

Persons: Biocon, Biocon Biologics

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

☆ Want to cash in on the weight-loss drug boom? Morgan Stanley names 4 global stocks
▼ + stars: | 2024-02-01 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

Under-the-radar stock picks Morgan Stanley reckons the way to play the obesity theme in Asia is through names involved in GLP-1 drug development that "could find upside in burgeoning overseas markets." Calling it "top beneficiary as global demand for GLP-1 drugs significantly outpaces capacity," Morgan Stanley has an overweight rating on the stock. Morgan Stanley has an investment horizon of just over six months for WuXi AppTec and Innovent and over 12 months for Chugai and EBOS. Morgan Stanley's analysts estimate that worldwide sales of Orforglipron could hit $7 billion in 2023. Elsewhere, it sees opportunities for EBOS following the Australian government's approval for it to distribute obesity drugs.

Persons: Eli Lilly, Morgan, Sean Wu, Morgan Stanley's, Health Organization's, Morgan Stanley, Chugai, Goldman, EBOS, CNBC's Michael Bloom Organizations: Novo Nordisk, Health, WHO, BMI, WuXi AppTec, Australian, Hong Kong Stock Exchange, China Health Care, Goldman Sachs, Health Care Equity, Zealand ETF Locations: U.S, Asia, Asia Pacific, Australia, GLP, WuXi, China, Japan, New Zealand, Zealand

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Opinion: The actual hidden truth about UFOs
▼ + stars: | 2024-01-26 | by ( Peter Bergen | ) edition.cnn.com time to read: +11 min

CNN —A former Pentagon official — driven, he says, by his duty to the truth — goes public with an explosive allegation. Facing a scrum of TV cameras and members of Congress, this official claims that the US government has been keeping crashed alien spaceships under wraps for decades. Crashed alien spacecraft and dead extraterrestrials, right there in the Congressional Record. Because, for decades, UFO true believers have been telling us there’s a US government conspiracy to hide evidence of aliens. But — if you believe Kirkpatrick — the more mundane truth is that these stories are being pumped up by a group of UFO true believers in and around government.

Persons: Peter Bergen, ”, Erik German, “, CNN —, David Grusch, he’d, Grusch, must’ve, Sean Kirkpatrick, Kirkpatrick, Tom Williams, ” Kirkpatrick, Naval Intelligence Scott Bray, Kevin Dietsch, It’s, you’ve, Harry Reid, Robert Bigelow, ’ ”, Sen, Chip Somodevilla, Reid, Bigelow, ” Reid, “ I’m, who’d Organizations: New, Arizona State University, Apple, Spotify, CNN, Pentagon, Air Force, SPAN, US Department of Defense, Defense, National Security, Foreign Affairs, Naval Intelligence, Intelligence, Capitol, Roswell Army Air Field, Army, Newspapers, Roswell, US Air Force, NASA Voyager, Walker, Roswell AAF, Reuters, Nevada Democrat, Bigelow Aerospace, US Defense Intelligence Agency, New York Times Locations: New America, Roswell, New Mexico, Florida, Nevada, Washington ,

☆ Morning Bid: Buoyant markets hold near year's highs
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +5 min

The Wall Street sign is pictured at the New York Stock exchange (NYSE) in the Manhattan borough of New York City, New York, U.S., March 9, 2020. Fed futures markets think a first cut may come as soon as March - with a quarter-point easing by then already two-thirds priced. Two-year Treasury yields hit their lowest since June on Friday and 10-year yields their lowest in three months, although they edged higher on Monday. U.S. crude hit its lowest in two weeks and is tracking year-on-year losses of almost 10%. But that is widening into yearend as peak rate hopes encourage some rotation to smaller cap stocks.

Persons: Carlo Allegri, Mike Dolan, Jerome Powell, Powell, Goldman Sachs, Jan, Fitch, Bitcoin, Christine Lagarde, Joann, Kirsten Donovan Organizations: New York Stock, REUTERS, Federal Reserve, Spelman College, Fed, Tech, HK, Central Bank, Treasury, PMI Reuters Graphics Reuters, Reuters, Thomson Locations: Manhattan, New York City , New York, U.S, Atlanta, Europe, Gaza, China, Hong Kong, WuXi, Evergrande, RGC Resources

☆ AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
▼ + stars: | 2023-12-03 | by ( ) www.reuters.com time to read: +1 min

The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File Photo Acquire Licensing RightsCompanies Absci Corp FollowAstraZeneca PLC FollowDec 3 (Reuters) - Anglo-Swedish drugmaker AstraZeneca (AZN.L) has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci (ABSI.O) to design an antibody to fight cancer, the Financial Times reported on Sunday. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. Absci and AstraZeneca did not immediately respond to a Reuters requests for comment. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.

Persons: Johanna Geron, Sean McClain, Absci’s, Shivani Tanna, William Mallard Organizations: AstraZeneca, REUTERS, U.S, Financial Times, Thomson Locations: Brussels, Belgium, Swedish, Bengaluru

CAPE TOWN, South Africa (AP) — South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. The pills are especially important for South Africa, where TB killed more than 50,000 people in 2021, making it the country’s leading cause of death. In July, J&J’s patent on the drug expired in South Africa, but the company had it extended until 2027, enraging activists who accused it of profiteering. Back then, President Nelson Mandela’s government in South Africa eventually suspended patents to allow wider access to AIDS drugs. Bedaquiline was not rolled out as a standard treatment in South Africa until 2018.

Persons: they’ve, ”, Brook Baker, Johnson, Christophe Perrin, Peter Maybarduk, Petro Terblanche, Afrigen, Nelson Mandela’s, “ Mandela, Terblanche, Lynette Keneilwe Mabote, Andy Gray, Gray, Zolelwa, Bedaquiline, “, Sifumba, ___ Cheng Organizations: Health Organization, Northeastern University, One, Johnson, J, Viiv Healthcare, WHO, Public Citizen, Pfizer, Moderna, Terblanche, Big Pharma, South, University of KwaZulu, World Health Organization, AP Locations: CAPE, South Africa, Colombia, Belarus, Ukraine, Colombian, Washington, Africa, Natal, South African, London

Search resuls for: "biologics"

25 mentions found